Screener
Kailera Therapeutics KLRA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026. Open the filing →
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
FAQ
- What is Kailera Therapeutics's cash & equivalents?
- Kailera Therapeutics (KLRA) reported cash & equivalents of $111.83M in Q1 2026.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Kailera Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude